{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:44:41Z","timestamp":1794516281133,"version":"4.9.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["healthpolicyjrnl.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.healthpol.2014.12.016","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T12:45:17Z","timestamp":1419943517000},"page":"964-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":261,"title":["Socio-economic burden of rare diseases: A systematic review of cost of illness evidence"],"prefix":"10.1016","volume":"119","author":[{"given":"Aris","family":"Angelis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tordrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Kanavos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healthpol.2014.12.016_bib0550","unstructured":"Eurordis. About rare diseases 2014. Available from: http:\/\/www.eurordis.org\/about-rare-diseases."},{"key":"10.1016\/j.healthpol.2014.12.016_bib0555","series-title":"Council Recommendation on action in the field of rare diseases \u2013 2947th Employment, social policy, health and consumer affairs \u2013 council meeting","author":"Council of the European Union","year":"2009"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0560","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ip.6.3.177","article-title":"Cost of illness studies: what is good about them?","volume":"6","author":"Rice","year":"2000","journal-title":"Injury Prevention"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0565","series-title":"Standards for the socioeconomic evaluation of healthcare services","author":"Luce","year":"1990"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0570","series-title":"Cost-of-illness studies \u2013 a primer","author":"Segel","year":"2006"},{"issue":"7245","key":"10.1016\/j.healthpol.2014.12.016_bib0575","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/bmj.320.7245.1335","article-title":"Cost of illness studies","volume":"320","author":"Byford","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0580","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/bmj.307.6907.793","article-title":"Economic evaluation and health care: cost-effectiveness analysis","volume":"307","author":"Robinson","year":"1993","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-199202010-00001","article-title":"Cost-of-illness studies: a major headache?","volume":"2","author":"Drummond","year":"1992","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0590","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/3349801","article-title":"Cost of illness methodology: a guide to current practices and procedures","volume":"60","author":"Hodgson","year":"1982","journal-title":"Milbank Memorial Fund Quarterly"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0595","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.healthpol.2012.08.001","article-title":"Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study","volume":"108","author":"Linertova","year":"2012","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0600","unstructured":"University of British Columbia. Pacific Exchange Rate Service. Available from: http:\/\/fx.sauder.ubc.ca\/data.html [cited 02.13]."},{"key":"10.1016\/j.healthpol.2014.12.016_bib0605","series-title":"World Economic Outlook Database April 2012","author":"IMF","year":"2012"},{"issue":"11","key":"10.1016\/j.healthpol.2014.12.016_bib0610","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1183\/09031936.96.09112215","article-title":"The nonhospital costs of care of patients with CF in The Netherlands: results of a questionnaire","volume":"9","author":"Wildhagen","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0615","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.19.15.1159.30580","article-title":"Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase","volume":"19","author":"Johnson","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib0620","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1569-1993(03)00024-9","article-title":"Cost of care and clinical condition in paediatric cystic fibrosis patients","volume":"2","author":"Baumann","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0625","series-title":"Prevalence of rare diseases: bibliographic data","author":"Orphanet Report Series","year":"2013"},{"issue":"14","key":"10.1016\/j.healthpol.2014.12.016_bib0630","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2165\/00019053-200321140-00002","article-title":"Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies","volume":"21","author":"Krauth","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0635","unstructured":"NIH. Duchenne muscular dystrophy 2010. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0001724 [cited 01.03.11]."},{"key":"10.1016\/j.healthpol.2014.12.016_bib0640","unstructured":"NFXF. What is Fragile X 2011 [cited 01.03.11]."},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0645","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G","article-title":"Prevalence of fragile X syndrome","volume":"64","author":"Turner","year":"1996","journal-title":"American Journal of Medical Genetics"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0650","unstructured":"Anaesthesia-UK. Haemophilia 2009. Available from: http:\/\/www.frca.co.uk\/article.aspx?articleid=100098 [cited 06.05.11]."},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0655","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.22463","article-title":"Economic impact of juvenile idiopathic arthritis","volume":"57","author":"Bernatsky","year":"2007","journal-title":"Arthritis Care & Research"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0660","series-title":"Genetics Home Reference: Mucopolysaccharidosis type I","author":"National Institutes of Health (NIH)","year":"2008"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0665","series-title":"Genetics Home Reference: Mucopolysaccharidosis type II","author":"National Institutes of Health (NIH)","year":"2008"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0670","series-title":"Genetics Home Reference: Mucopolysaccharidosis type III","author":"National Institutes of Health (NIH)","year":"2008"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0675","series-title":"Genetics Home Reference: Mucopolysaccharidosis type IV","author":"National Institutes of Health (NIH)","year":"2008"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0680","series-title":"Genetics Home Reference: Mucopolysaccharidosis type VI","author":"National Institutes of Health (NIH)","year":"2008"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0685","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007990902892633","article-title":"Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI","volume":"25","author":"Schlander","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0690","series-title":"Scleroderma","author":"National Institutes of Health (NIH)","year":"2011"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0695","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.24339","article-title":"Scleroderma prevalence: demographic variations in a population-based sample","volume":"61","author":"Bernatsky","year":"2009","journal-title":"Arthritis Care & Research"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0700","series-title":"Prader-Willi Syndrome: PubMed Health","author":"National Institutes of Health (NIH)","year":"2011"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0705","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S001216220100202X","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study","volume":"44","author":"Butler","year":"2002","journal-title":"Developmental Medicine & Child Neurology"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0710","first-page":"500","article-title":"Growth hormone therapy in children and adults","volume":"59","author":"Krysiak","year":"2007","journal-title":"Anglais"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0715","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3111\/13696990903245863","article-title":"Cost of illness associated with Niemann-Pick disease type C in the UK","volume":"12","author":"Imrie","year":"2009","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0720","series-title":"Niemann-Pick disease type C","author":"Patterson","year":"2000"},{"issue":"6","key":"10.1016\/j.healthpol.2014.12.016_bib0725","first-page":"715","article-title":"Cost analysis of the Kozak protocol as used in an Ontario hospital in the treatment of children with epidermolysis bullosa","volume":"130","author":"Wodinsky","year":"1984","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0730","series-title":"Genetic Home Reference: Epidermolysis bullosa simplex","author":"National Institutes of Health (NIH)","year":"2007"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0735","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/thx.51.3.298","article-title":"Cost of care of patients with cystic fibrosis in The Netherlands in 1990\u20131","volume":"51","author":"Wildhagen","year":"1996","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0740","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hec.4730030104","article-title":"Cost-benefit analysis of a national screening programme for cystic fibrosis in an israeli population","volume":"3","author":"Ginsberg","year":"1994","journal-title":"Health Economics"},{"issue":"12","key":"10.1016\/j.healthpol.2014.12.016_bib0745","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00063-010-1154-z","article-title":"Drug treatment of cystic fibrosis \u2013 cost patterns and savings potential for outpatient treatment","volume":"105","author":"Baltin","year":"2010","journal-title":"Medizinische Klinik (Munich, Germany: 1983)"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib0750","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.rbmo.2010.04.031","article-title":"PGD for all cystic fibrosis carrier couples: novel strategy for preventive medicine and cost analysis","volume":"21","author":"Tur-Kaspa","year":"2010","journal-title":"Reproductive BioMedicine Online"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0755","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hec.652","article-title":"Prenatal screening for cystic fibrosis: an economic analysis","volume":"11","author":"Nielsen","year":"2002","journal-title":"Health Economics"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0760","series-title":"Textbook of cystic fibrosis","first-page":"465","article-title":"The economics of cystic fibrosis","author":"Pauly","year":"1983"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0765","series-title":"Cystic fibrosis and DNA tests: implications of carrier screening","author":"US-OTA","year":"1992"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0770","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1017\/S0266462307080075","article-title":"Valuing care recipient and family caregiver time: a comparison of methods","volume":"24","author":"Guerriere","year":"2008","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"6","key":"10.1016\/j.healthpol.2014.12.016_bib0775","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1542\/peds.103.6.e72","article-title":"The cost of medical care for patients with cystic fibrosis in a health maintenance organization","volume":"103","author":"Lieu","year":"1999","journal-title":"Pediatrics"},{"issue":"9568","key":"10.1016\/j.healthpol.2014.12.016_bib0780","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(07)60565-0","article-title":"Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study","volume":"369","author":"Sims","year":"2007","journal-title":"The Lancet"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0785","first-page":"626","article-title":"Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment","volume":"92","author":"Graf von der Schulenburg","year":"1997","journal-title":"Medizinische Klinik (Munich, Germany: 1983)"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib0790","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1179\/joc.2009.21.2.188","article-title":"The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"21","author":"Braccini","year":"2009","journal-title":"Journal of Chemotherapy"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0795","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2008.02.004","article-title":"Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network","volume":"7","author":"Huot","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0800","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ppul.21090","article-title":"Healthcare expenditures for privately insured people with cystic fibrosis","volume":"44","author":"Ouyang","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib0805","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1542\/peds.100.2.197","article-title":"Expenditures for care of children with chronic illnesses enrolled in the washington state medicaid program. Fiscal year 1993","volume":"100","author":"Ireys","year":"1997","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0810","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0149-2918(00)87985-0","article-title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","volume":"22","author":"LeLorier","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0815","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/106002809502900501","article-title":"Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis","volume":"29","author":"Oster","year":"1995","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.healthpol.2014.12.016_bib0820","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2648.1995.tb03106.x","article-title":"Home treatment of patients with cystic fibrosis using the \u2018Intermate\u2019: the first year's experience","volume":"22","author":"Bramwell","year":"1995","journal-title":"Journal of Advanced Nursing"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0825","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/BF03044951","article-title":"Cost comparison of hospital and ambulatory iv therapy in adult cystic fibrosis patients. Results of a controlled prospective study","volume":"94","author":"Krauth","year":"1999","journal-title":"Medizinische Klinik (Munich, Germany: 1983)"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0830","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2165\/00019053-200624100-00007","article-title":"Hospitalisation costs of cystic fibrosis","volume":"24","author":"Schreyogg","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib0835","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00063-009-1112-9","article-title":"Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results","volume":"104","author":"Eidt","year":"2009","journal-title":"Medizinische Klinik (Munich, Germany: 1983)"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0840","first-page":"220","article-title":"Socioeconomic evaluation of the influence of rhDNase on the costs of treating respiratory-tract infections in patients with cystic-fibrosis","volume":"90","author":"Graf von der Schulenburg","year":"1995","journal-title":"Medizinische Klinik"},{"issue":"9","key":"10.1016\/j.healthpol.2014.12.016_bib0845","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/thx.47.9.684","article-title":"A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients","volume":"47","author":"Robson","year":"1992","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0850","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1345\/aph.19159","article-title":"Use of rhDNase therapy and costs of respiratory-related care in patients with cystic fibrosis","volume":"34","author":"Ollendorf","year":"2000","journal-title":"Annals of Pharmacotherapy"},{"issue":"04","key":"10.1016\/j.healthpol.2014.12.016_bib0855","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1017\/S0266462305050701","article-title":"Comparing costs of home- versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center","volume":"21","author":"Elliott","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"04","key":"10.1016\/j.healthpol.2014.12.016_bib0860","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1017\/S0266462306051476","article-title":"Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France","volume":"22","author":"Horvais","year":"2006","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0865","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1086\/302042","article-title":"Prenatal screening for cystic fibrosis carriers: an economic evaluation","volume":"63","author":"Rowley","year":"1998","journal-title":"American Journal of Human Genetics"},{"issue":"9","key":"10.1016\/j.healthpol.2014.12.016_bib0870","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jmg.34.9.741","article-title":"Cost effectiveness of DNA diagnosis for four monogenic diseases","volume":"34","author":"van der Riet","year":"1997","journal-title":"Journal of Medical Genetics"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0875","first-page":"245","article-title":"Outpatient rehabilitation for chronic neuromuscular diseases","volume":"65","author":"Koch","year":"1986","journal-title":"American Journal of Physical Medicine"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0880","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0277-9536(93)90289-G","article-title":"Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy \u2013 how does this compare to existing neonatal screening for metabolic disorders?","volume":"37","author":"Rosenberg","year":"1993","journal-title":"Social Science & Medicine"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib0885","first-page":"1","article-title":"An assessment of screening strategies for fragile X syndrome in the UK","volume":"5","author":"Pembrey","year":"2001","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib0890","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1086\/321974","article-title":"Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel","volume":"69","author":"Toledano-Alhadef","year":"2001","journal-title":"American Journal of Human Genetics"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0895","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000016133","article-title":"Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general population","volume":"1","author":"Wildhagen","year":"1998","journal-title":"Community Genetics"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0900","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2788.2010.01320.x","article-title":"Employment impact and financial burden for families of children with fragile X syndrome: findings from the National Fragile X Survey","volume":"54","author":"Ouyang","year":"2010","journal-title":"Journal of Intellectual Disability Research"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0905","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2516.2003.00811.x","article-title":"An economic model of haemophilia in Mexico","volume":"10","author":"Mart\u00ednez-Murillo","year":"2004","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0910","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.2002.00580.x","article-title":"Clinical outcomes and resource utilization associated with haemophilia care in Europe","volume":"8","author":"Schramm","year":"2002","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0915","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2516.2004.00952.x","article-title":"Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden","volume":"10","author":"Carlsson","year":"2004","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0920","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2516.1996.tb00139.x","article-title":"Socioeconomic impact of haemophilia care: results of a pilot study","volume":"2","author":"Szucs","year":"1996","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib0925","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0930","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2516.2006.01370.x","article-title":"Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors","volume":"12","author":"Ullman","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib0935","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2516.2003.00849.x","article-title":"The economic impact of factor VIII inhibitors in patients with haemophilia","volume":"10","author":"Bohn","year":"2004","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0940","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2516.2007.01495.x","article-title":"A haemophilia treatment centre-administered disease management programme in patients with bleeding disorders","volume":"13","author":"Tencer","year":"2007","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0945","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2516.2005.01082.x","article-title":"Cost of severe haemophilia in Toronto","volume":"11","author":"Heemstra","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.healthpol.2014.12.016_bib0950","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1355-0691.2004.00881.x","article-title":"Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS)","volume":"10","author":"Globe","year":"2004","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0955","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11096-007-9181-4","article-title":"Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres","volume":"30","author":"Nerich","year":"2008","journal-title":"Pharmacy World & Science"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib0960","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-2516.2007.01522.x","article-title":"A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil","volume":"13","author":"Ozelo","year":"2007","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0965","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2516.2005.01098.x","article-title":"A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors","volume":"11","author":"Putnam","year":"2005","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib0970","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00019053-200321100-00002","article-title":"Determinants of drug costs in hospitalised patients with haemophilia: impact of recombinant activated factor VII","volume":"21","author":"Galanaud","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.healthpol.2014.12.016_bib0975","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2516.1999.00321.x","article-title":"The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada","volume":"5","author":"Chang","year":"1999","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.healthpol.2014.12.016_bib0980","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2516.1999.00368.x","article-title":"Treatment of patients with inhibitors: cost issues","volume":"5","author":"Goudemand","year":"1999","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib0985","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00002030-199507000-00017","article-title":"Hospital costs of treating haetnophilic patients infected with HIV","volume":"9","author":"Kennelly","year":"1995","journal-title":"Aids"},{"issue":"9","key":"10.1016\/j.healthpol.2014.12.016_bib0990","doi-asserted-by":"crossref","first-page":"790","DOI":"10.18553\/jmcp.2007.13.9.790","article-title":"Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection","volume":"13","author":"Tencer","year":"2007","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"3","key":"10.1016\/j.healthpol.2014.12.016_bib0995","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2516.2009.02179.x","article-title":"The value of early treatment in patients with haemophilia and inhibitors","volume":"16","author":"Kavakli","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib1000","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1365-2516.2002.00671.x","article-title":"Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres","volume":"8","author":"Gautier","year":"2002","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib1005","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2516.2004.00950.x","article-title":"Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany","volume":"10","author":"Auerswald","year":"2004","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.healthpol.2014.12.016_bib1010","first-page":"2286","article-title":"Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis","volume":"31","author":"Haapasaari","year":"2004","journal-title":"Journal of Rheumatology"},{"issue":"39","key":"10.1016\/j.healthpol.2014.12.016_bib1015","first-page":"1","article-title":"Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis","volume":"9","author":"Epps","year":"2005","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib1020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/ard.2003.008516","article-title":"Burden and cost of illness in patients with juvenile idiopathic arthritis","volume":"63","author":"Minden","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1016\/j.healthpol.2014.12.016_bib1025","first-page":"863","article-title":"The economic burden of juvenile idiopathic arthritis-results from the German paediatric rheumatologic database","volume":"27","author":"Minden","year":"2009","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"7","key":"10.1016\/j.healthpol.2014.12.016_bib1030","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/rheumatology\/ken039","article-title":"Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis","volume":"47","author":"Thornton","year":"2008","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.healthpol.2014.12.016_bib1035","first-page":"952","article-title":"The economic impacts of juvenile rheumatoid arthritis","volume":"19","author":"Allaire","year":"1992","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.healthpol.2014.12.016_bib1040","first-page":"S686","article-title":"Effects of treatment on costs & health-related quality of life (HRQL) of children with polyarticular course juvenile rheumatoid arthritis (JRA)","volume":"50","author":"Brunner","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"17","key":"10.1016\/j.healthpol.2014.12.016_bib1045","doi-asserted-by":"crossref","DOI":"10.3310\/hta6170","article-title":"A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept","volume":"6","author":"Cummins","year":"2002","journal-title":"Health Technology Assessment"},{"issue":"20","key":"10.1016\/j.healthpol.2014.12.016_bib1050","first-page":"113","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib1055","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/art.24086","article-title":"The cost of systemic sclerosis","volume":"61","author":"Bernatsky","year":"2009","journal-title":"Arthritis Care & Research"},{"issue":"2","key":"10.1016\/j.healthpol.2014.12.016_bib1060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-0172(97)80008-X","article-title":"Cost-of-illness of scleroderma: the case for rare diseases","volume":"27","author":"Wilson","year":"1997","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.healthpol.2014.12.016_bib1065","series-title":"Cost-of-illness in systemic sclerosis: a retrospective study of an italian cohort of 106 patients","author":"Belotti Masserini","year":"2011"},{"issue":"10","key":"10.1016\/j.healthpol.2014.12.016_bib1070","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/rheumatology\/keq165","article-title":"Cost-of-illness of patients with systemic sclerosis in a tertiary care centre","volume":"49","author":"Minier","year":"2010","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.healthpol.2014.12.016_bib1075","first-page":"1526","article-title":"Cost analysis of the Kozak protocol in the treatment of epidermolysis bullosa","volume":"130","author":"Ramsay","year":"1984","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10.1016\/j.healthpol.2014.12.016_bib1080","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.healthpol.2014.12.016_bib1085","unstructured":"European Commission. Implementation report on the Commission Communication on Rare Diseases: Europe's challenges [COM(2008) 679 final] and Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009\/C 151\/02) 2009. Available from: http:\/\/ec.europa.eu\/health\/rare_diseases\/docs\/2014_rarediseases_implementationreport_en.pdf."},{"key":"10.1016\/j.healthpol.2014.12.016_bib1090","unstructured":"OECD. A System of Health Accounts: Organisation for Economic Co-operation and Development. Available from: http:\/\/www.oecd.org\/health\/sha [cited 03.05.13]."}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851014003509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851014003509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T01:59:55Z","timestamp":1717639195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851014003509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0168851014003509"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Socio-economic burden of rare diseases: A systematic review of cost of illness evidence","name":"articletitle","label":"Article Title"},{"value":"Health Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healthpol.2014.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}